about
Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumorsHSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic VirusesVaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic PotencyTargeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ InhibitorsCART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Immune System, Friend or Foe of Oncolytic Virotherapy?
@en
Immune System, Friend or Foe of Oncolytic Virotherapy?
@nl
type
label
Immune System, Friend or Foe of Oncolytic Virotherapy?
@en
Immune System, Friend or Foe of Oncolytic Virotherapy?
@nl
prefLabel
Immune System, Friend or Foe of Oncolytic Virotherapy?
@en
Immune System, Friend or Foe of Oncolytic Virotherapy?
@nl
P2860
P356
P1476
Immune System, Friend or Foe of Oncolytic Virotherapy?
@en
P2093
Anna C Filley
P2860
P356
10.3389/FONC.2017.00106
P407
P50
P577
2017-05-23T00:00:00Z